Reactogenicity and immunogenicity of a single dose of typhoid Vi polysaccharide vaccine in children aged between 4 and 14 years

BioDrugs

Volumn 15, Issue SUPPL. 1, 2001, Pages 13-19

  Pelser, Helena H ^a  

^a NONE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

TYPHERIX; TYPHOID VACCINE;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CALCULATION; CHILD; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; MALE; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; TYPHOID FEVER;

EID: 0035208507     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115001-00003     Document Type: Article

References (10)

1. Mermin JH, Townes JM, Gerber M, et al. Typhoid fever in the United States, 1985-1994: changing risks of international travel and increasing antimicrobial resistance. Arch Intern Med 1998; 158: 633-8
2. World Health Organization. International travel and health: vaccination requirements and health advice. Last updated Jan 2000. Available from: URL: http://www.who.int/ith/english/
3. Centers for Disease Control and Prevention. Typhoid immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994; 43 (No. RR-14): 1-7
4. Cryz Jr SJ. Patient compliance in the use of Vivotif Berna® vaccine, typhoid vaccine, live oral Ty21a. J Travel Med 1998; 5: 14-7
5. Warren TA, Finder SF, Brier KL, et al. A cost-effectiveness analysis of typhoid fever vaccines in US military personnel. Pharmacoeconomics 1996; 10: 475-83
6. Plotkin SA, Bouveret-Le Cam N. A new typhoid vaccine composed of the Vi capsular polysaccharide. Arch Intern Med 1995; 155: 2293-9
7. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987; 317: 1101-4
8. Klugman KP, Koornhof HJ, Robbins JB, et al. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 1996; 14: 435-8
9. Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263-9
10. Cumberland NS, St Clair Roberts J, Arnold WS, et al. Typhoid Vi: a less reactogenic vaccine. J Int Med Res 1992; 20: 247-53